Pembrolizumab Significantly Improves Event-Free Survival in Head and Neck Cancer: NEJM
According to a recent study adding perioperative pembrolizumab to standard therapy such as surgery and radiotherapy with or without cisplatin consistently improves event-free survival (EFS) in patients with locally advanced head and neck squamous-cell carcinoma (HNSCC), researchers have discovered. Significantly, this increase in EFS was seen in patients with various levels of programmed death ligand […]